tradingkey.logo

Smith & Nephew PLC

SNN
View Detailed Chart
34.690USD
-0.480-1.36%
Close 02/06, 16:00ETQuotes delayed by 15 min
15.19BMarket Cap
30.87P/E TTM

Smith & Nephew PLC

34.690
-0.480-1.36%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.36%

5 Days

+1.61%

1 Month

+2.33%

6 Months

-2.28%

Year to Date

+5.73%

1 Year

+37.39%

View Detailed Chart

TradingKey Stock Score of Smith & Nephew PLC

Currency: USD Updated: 2026-02-06

Key Insights

Smith & Nephew PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 69 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.83.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Smith & Nephew PLC's Score

Industry at a Glance

Industry Ranking
69 / 205
Overall Ranking
182 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Smith & Nephew PLC Highlights

StrengthsRisks
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.81B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.
Undervalued
The company’s latest PE is 30.87, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.25M shares, decreasing 24.19% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 203.99K shares of this stock.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
33.833
Target Price
-3.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Smith & Nephew PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Smith & Nephew PLC Info

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Ticker SymbolSNN
CompanySmith & Nephew PLC
CEONath (Deepak S)
Websitehttps://www.smith-nephew.com/
KeyAI